Adial Pharmaceuticals Approves Restricted Stock Grants for Executive Officers and Directors

On April 7, 2026, the Compensation Committee of the Board of Directors of Adial Pharmaceuticals, Inc. approved the grant of restricted stock awards (RSAs) to its named executive officers and certain directors. Cary Claiborne, CEO and Director, received 37,985 RSAs; Vinay Shah, CFO, received 17,325 RSAs; and Tony Goodman, COO and Director, received 26,510 RSAs. Additionally, directors Kevin Schuyler and Robertson H. Gilliland were each granted 9,185 RSAs, while director Kermit Anderson received options to purchase 9,185 shares of common stock at an exercise price of $1.64 per share. All RSAs are scheduled to vest in full on the earlier of the one-year anniversary of the grant date or upon a Change of Control, as defined in the company's 2017 Equity Incentive Plan. The Board also approved a new form of Restricted Stock Award Agreement to facilitate these grants. These awards are intended to align executive and director interests with the long-term success and growth of the company.